Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: Conditions for cloning T cells from psoriatic plaques

Experimental Dermatology

Volumn 13, Issue 10, 2004, Pages 607-612

  Kohlmann, Wayan M ^a   Urban, Wiebke ^a   Sterry, Wolfram ^a   Foerster, John ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD25; Clone; Psoriasis; T cells

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; PATHOGENESIS; PHENOTYPE; PSORIASIS; T LYMPHOCYTE;

ANTIGENS, CD3; ANTIGENS, CD8; CD4-CD8 RATIO; CLONING, MOLECULAR; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTE ACTIVATION; PSORIASIS; RECEPTORS, INTERLEUKIN-2; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 5144225433     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00195.x     Document Type: Article

References (32)

1. Prinz J C. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003: 17: 257-270.
2. + T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci USA 1994: 91: 9282-9286.
3. Boehncke W H, Dressel D, Manfras B et al. T-cell-receptor repertoire in chronic plaque-stage psoriasis is restricted and lacks enrichment of superantigen-associated V beta regions. J Invest Dermatol 1995: 104: 725-728.
4. Menssen A, Trommler P, Vollmer S et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995: 155: 4078-4083.
5. Ahangari G, Halapi E, Tehrani M J, Fransson J, Hammar H, Wigzell H. RT-PCR topography of chronic psoriasis skin based on analysis of T-cell receptor B variable region gene usage. Scand J Immunol 1997: 45: 534-540.
6. Moss P, Charmley P, Mulvihill E et al. The repertoire of T cell antigen receptor beta-chain variable regions associated with psoriasis vulgaris. J Invest Dermatol 1997: 109: 14-19.
7. Lin W J, Norris D A, Achziger M, Kotzin B L, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 2001: 117: 1546-1553.
8. Vollmer S, Menssen A, Prinz J C. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 2001: 117: 1296-1301.
9. Sakkas L I, Xu B, Artlett C M, Lu S, Jimenez S A, Platsoucas C D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002: 168: 3649-3659.
10. Prinz J C, Gross B, Vollmer S et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994: 24: 593-598.
11. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz J C. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994: 24: 2377-2382.
12. Ferenczi K, Burack L, Pope M, Krueger J G, Austin L M. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000: 14: 63-78.
13. Prinz J C. Which T cells cause psoriasis? Clin Exp Dermatol 1999: 24: 291-295.
14. + subsets. J Invest Dermatol 1998: 111: 1072-1078.
15. + T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol 2000: 114: 576-580.
16. Horrocks C, Holder J E, Berth-Jones J, Camp R D. Antigen-independent expansion of T cells from psoriatic skin lesions: phenotypic characterization and antigen reactivity. Br J Dermatol 1997: 137: 331-338.
17. + T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma. Exp Dermatol 2001: 10: 168-174.
18. Pinilla C, Martin R, Gran B et al. Exploring immunological specificity using synthetic peptide combinatorial libraries. Curr Opin Immunol 1999: 11: 193-202.
19. Matsushita S, Tanaka Y, Matsuoka T, Nakashima T. Clonal expansion of freshly isolated CD4T cells by randomized peptides and identification of peptide ligands using combinatorial peptide libraries. Eur J Immunol 2001: 31: 2395-2402.
20. Rathmell J C, Farkash E A, Gao W, Thompson C B. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001: 167: 6869-6876.
21. Krueger J G, Wolfe J T, Nabeya R T et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995: 182: 2057-2068.
22. De Pita O, Ruffelli M, Cadoni S et al. Psoriasis: comparison of immunological markers in patients with acute and remission phase. J Dermatol Sci 1996: 13: 118-124.
23. De Rie M A, Zonneveld I M, Witkamp L, Van Lier R A, Out T A, Bos J D. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 1996: 76: 357-360.
24. + T cells induces psoriasis. Am J Pathol 1999: 155: 145-158.
25. + T lymphocytes in psoriatic arthritis. J Rheumatol 1999: 26: 1117-1124.
26. Mallon E, Bunker C B. HIV-associated psoriasis. AIDS Patient Care STDS 2000: 14: 239-246.
27. Hida S, Ogasawara K, Sato K et al. CD8 (+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000: 13: 643-655.
28. + T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001: 126: 365-369.
29. Nguyen T, Russell J. The regulation of FasL expression during activation-induced cell death (AICD). Immunology 2001: 103: 426-434.
30. Rathmell J C, Thompson C B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002: 109 (Suppl.): S97-S1O7.
31. Hildeman D A, Mitchell T, Teague T K et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999: 10: 735-744.
32. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999: 189: 521-530.